Robot-assisted axillary lymph node dissection (RALND) has been proposed to improve surgical and oncological outcomes for patients with breast cancer. To perform a systematic review of current literature evaluating RALND in patients with invasive breast cancer. A systematic search was performed in accordance with the PRISMA guidelines. Studies outlining outcomes following RALND were included. Two studies involving 92 patients were included in this review. Of these, 41 underwent RALND using the da Vinci^© robotic system (44.57%), and 51 underwent conventional axillary lymph node dissection (CALND) (55.43%). There was no significant difference observed with respect to intra-operative blood loss or duration of procedure in those undergoing CALND and RALND (P > 0.050). One study reported a significant difference in lymphoedema rates in support of RALND (6.67% vs 26.67%, P = 0.038). Overall, data in relation to postoperative fat necrosis (10.00% vs 33.33%, P = 0.028), wound infection rates (3.33% vs. 20.00%, P = 0.044), and wound ≤ 40 mm in length (63.63% vs. 19.05%, P = 0.020) supported RALND. Oncological outcomes were only reported in one of the studies, which concluded that there was no local or metastatic recurrence in either group at 3-month follow-up. These provisional results support RALND as a safe alternative to CALND. Notwithstanding, the paucity of data limits the robustness of conclusions which may be drawn surrounding the adoption of RALND as the standard of care. Further high-quality studies are required to ratify these findings.

机器人辅助腋窝淋巴结清扫术（RALND）已被提议用于改善乳腺癌患者的手术和肿瘤学结果。对评估浸润性乳腺癌患者 RALND 的当前文献进行系统回顾。根据 PRISMA 指南进行系统检索。概述 RALND 后结果的研究也被纳入其中。本综述纳入了两项涉及 92 名患者的研究。其中，41 例使用达芬奇^©机器人系统接受 RALND（44.57%），51 例接受传统腋窝淋巴结清扫术（CALND）（55.43%）。接受 CALND 和 RALND 的患者术中失血量或手术持续时间没有显着差异（P  > 0.050）。一项研究报告支持 RALND 的淋巴水肿发生率存在显着差异（6.67% vs 26.67%，P  = 0.038）。总体而言，与术后脂肪坏死（10.00% vs. 33.33%， P  = 0.028）、伤口感染率（3.33% vs. 20.00%，P  = 0.044）和伤口长度≤ 40 mm（63.63% vs. 19.05）相关的数据％，P  = 0.020）支持 RALND。其中一项研究仅报告了肿瘤学结果，该研究得出的结论是，在 3 个月的随访中，两组均未出现局部或转移性复发。这些临时结果支持 RALND 作为 CALND 的安全替代品。尽管如此，数据的缺乏限制了围绕采用 RALND 作为护理标准可能得出的结论的稳健性。需要进一步的高质量研究来证实这些发现。